255 related articles for article (PubMed ID: 12679216)
1. Hypertension, angiotensin II, aldosterone, and race.
Ben-Yehuda O
J Am Coll Cardiol; 2003 Apr; 41(7):1156-8. PubMed ID: 12679216
[No Abstract] [Full Text] [Related]
2. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
[TBL] [Abstract][Full Text] [Related]
3. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
5. Effects of eplerenone versus losartan in patients with low-renin hypertension.
Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
George J; Struthers AD
Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Miller AB; Srivastava P
Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
[TBL] [Abstract][Full Text] [Related]
9. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone: a review of its use in essential hypertension.
Croom KF; Perry CM
Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
[TBL] [Abstract][Full Text] [Related]
11. [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Derer W; Dechend R; Müller DN
MMW Fortschr Med; 2010 Feb; 152(6):48-9. PubMed ID: 20302183
[No Abstract] [Full Text] [Related]
12. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
13. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
Sato A; Fukuda S
J Hum Hypertens; 2010 Jun; 24(6):387-94. PubMed ID: 19865106
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone receptor antagonists: focus on eplerenone.
Lamb RE; Folstad J
Prog Cardiovasc Nurs; 2003; 18(1):54-9. PubMed ID: 12624573
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
17. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
[TBL] [Abstract][Full Text] [Related]
18. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Hameedi A; Chadow HL
Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
[TBL] [Abstract][Full Text] [Related]
19. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]